                         SEQUENCE LISTING

<110>  Yale University
       The United States Government as represented by the 
       Department of Veteran Affairs
       Hansen, James E.
       Weisbart, Richard
       Noble, Philip
       Young, Melissa
 
<120>  CELL PENETRATING ANTI-GUANOSINE  ANTIBODY BASED THERAPY FOR 
       CANCERS WITH RAS MUTATIONS

<130>  YU 6265

<150>  61/947,492
<151>  2014-03-04

<160>  22    

<170>  PatentIn version 3.5

<210>  1
<211>  107
<212>  PRT
<213>  Mus musculus

<400>  1

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr 
            20                  25                  30          


Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ile Ser Val Glu Thr 
65                  70                  75                  80  


Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp Pro Leu 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  2
<211>  11
<212>  PRT
<213>  Mus musculus

<400>  2

Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu His 
1               5                   10      


<210>  3
<211>  7
<212>  PRT
<213>  Mus musculus

<400>  3

Tyr Ala Ser Gln Ser Ile Ser 
1               5           


<210>  4
<211>  9
<212>  PRT
<213>  Mus musculus

<400>  4

Gln Gln Ser Asn Ser Trp Pro Leu Thr 
1               5                   


<210>  5
<211>  116
<212>  PRT
<213>  Mus musculus

<400>  5

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Val Asn Pro Ser Asn Gly Gly Ile Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Leu Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Pro Tyr Thr Met Tyr Tyr Trp Gly Gln Gly Thr Ser Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  6
<211>  5
<212>  PRT
<213>  Mus musculus

<400>  6

Asp Tyr Tyr Met Asn 
1               5   


<210>  7
<211>  17
<212>  PRT
<213>  Mus musculus

<400>  7

Arg Val Asn Pro Ser Asn Gly Gly Ile Ser Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  8
<211>  7
<212>  PRT
<213>  Mus musculus

<400>  8

Gly Pro Tyr Thr Met Tyr Tyr 
1               5           


<210>  9
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial polypeptide linker

<400>  9

Gly Gln Ser Ser Arg Ser Ser 
1               5           


<210>  10
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artifical polypeptide linker

<400>  10

Gly Gln Ser Ser Arg Ser Ser Ser Gly Gly Gly Ser Ser Gly Gly Gly 
1               5                   10                  15      


Gly Ser 
        


<210>  11
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial polypeptide linker

<400>  11

Gly Ser Gly Ser Gly Ser 
1               5       


<210>  12
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artifical polypeptide linker

<400>  12

Ala Ser Gly Gly Gly Ser 
1               5       


<210>  13
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artifical polypeptide linker

<400>  13

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  14
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial polypeptide linker

<400>  14

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
1               5                   10                  15      


Gly Gly Gly Ser 
            20  


<210>  15
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial polypeptide linker

<400>  15

Gly Gly Ser Ser Arg Ser Ser Ser Ser Gly Gly Gly Gly Ser Gly Gly 
1               5                   10                  15      


Gly Gly 
        


<210>  16
<211>  11
<212>  PRT
<213>  Human immunodeficiency virus

<400>  16

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   10      


<210>  17
<211>  9
<212>  PRT
<213>  Human immunodeficiency virus

<400>  17

Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial polypeptide sequence

<400>  18

Arg Arg Arg Arg Arg Arg Arg 
1               5           


<210>  19
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial polypeptide sequence

<400>  19

Arg Arg Gln Arg Arg Thr Ser Lys Leu Met Lys Arg 
1               5                   10          


<210>  20
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial polypeptide sequence

<400>  20

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu 
1               5                   10                  15      


Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 
            20                  25          


<210>  21
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial polypeptide sequence

<400>  21

Trp Glu Ala Lys Leu Ala Lys Ala Leu Ala Lys Ala Leu Ala Lys His 
1               5                   10                  15      


Leu Ala Lys Ala Leu Ala Lys Ala Leu Lys Cys Glu Ala 
            20                  25                  


<210>  22
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artifiical polypeptide sequence

<400>  22

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


